Swiss National Bank Acquires 1,200 Shares of IDEAYA Biosciences, Inc. $IDYA

Swiss National Bank grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 0.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 150,800 shares of the company’s stock after purchasing an additional 1,200 shares during the period. Swiss National Bank owned about 0.17% of IDEAYA Biosciences worth $2,470,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. grew its stake in IDEAYA Biosciences by 33.2% during the first quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company’s stock worth $189,000 after buying an additional 2,884 shares in the last quarter. Rhumbline Advisers raised its position in shares of IDEAYA Biosciences by 9.6% in the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company’s stock valued at $2,038,000 after buying an additional 10,876 shares in the last quarter. Palumbo Wealth Management LLC lifted its holdings in shares of IDEAYA Biosciences by 65.8% during the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company’s stock worth $367,000 after acquiring an additional 8,893 shares during the period. Deerfield Management Company L.P. Series C lifted its holdings in shares of IDEAYA Biosciences by 5.5% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company’s stock worth $70,315,000 after acquiring an additional 142,000 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of IDEAYA Biosciences by 25.3% during the 1st quarter. Deutsche Bank AG now owns 467,461 shares of the company’s stock worth $7,657,000 after acquiring an additional 94,482 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Up 2.0%

Shares of IDYA opened at $25.12 on Friday. The stock has a market cap of $2.20 billion, a PE ratio of -6.63 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $40.74. The business has a 50-day simple moving average of $22.98 and a two-hundred day simple moving average of $20.42.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the prior year, the business posted ($0.68) EPS. The company’s revenue was up NaN% on a year-over-year basis. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Wall Street Analyst Weigh In

IDYA has been the subject of several research analyst reports. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and lowered their price objective for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. The Goldman Sachs Group upgraded IDEAYA Biosciences to a “hold” rating and set a $25.00 price target on the stock in a research note on Thursday, July 10th. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They set an “overweight” rating and a $44.00 price target for the company. TD Cowen started coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Monday, July 28th. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.